Association study of cathepsin D gene polymorphism in iranian patients with sporadic late-onset alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 37, Issue 5-6, 2014, Pages 257-264

  Sayad, Azadeh ^a   Noruzinia, Mehrdad ^a   Zamani, Mahdi ^b   Harirchian, Mohammad Hossein ^c   Kazemnejad, Anoushiravan ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer's disease; Association study; Cathepsin D; Polymorphism; Amyloid

Indexed keywords

APOLIPOPROTEIN E4; CATHEPSIN D; DNA; CTSD PROTEIN, HUMAN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DSM-IV-TR; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEUROPATHOLOGY; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; APOLIPOPROTEIN E4 GENE; CATHEPSIN D GENE; GENE; GENETIC RISK; PATHOGENESIS; POLYMERASE CHAIN REACTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IRAN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; CATHEPSIN D; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IRAN; MALE; POLYMORPHISM, GENETIC;

EID: 84902478607     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000347128     Document Type: Article

References (68)

1. Strang J, Metrebian N, Lintzeris N, Potts L, Carnwath T, Mayet S, Williams H, Zador D, Evers R, Groshkova T, et al: Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): A randomised trial. Lancet 2010; 375: 1885-1895
2. Naber D, Haasen C: Das Bundesdeutsche Modellprojekt zur heroingestützten Behandlung Opiatabhängiger. Abschlussbericht zur klinischen Vergleichsstudie zur Heroin- und Methadonbehandlung. Hamburg, ZIS der Universität Hamburg, 2006
3. Ferri M, Davoli M, Perucci CA: Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2011;CD003410
4. Strang J, Groshkova T, Metrebian N: New heroin assisted treatment. Recent evidence and current practices of supervised injected heroin treatment in Europe and beyond. Luxembourg, Publications Office of the European Union, 2012
5. Uchtenhagen A: Heroin-Assisted treatment in Switzerland: A case study in policy change. Addiction 2010; 105: 29-37
6. Perneger TV, Giner F, del Rio M, Mino A: Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317: 13-18. (Pubitemid 28333818)
7. Bammer G, van den Brink W, Gschwend P, Hendriks V, Rehm J: What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug Alcohol Rev 2003; 22: 363-371
8. Sprumont D: Ethical evaluation of heroinprescription research: An insider's view. Am J Bioeth 2002; 2: 63-64
9. Ostini R, Bammer G, Dance PR, Goodin RE: The ethics of experimental heroin maintenance. J Med Ethics 1993; 19: 175-182. (Pubitemid 23297055)
10. Swiss Federal Council: Bundesratsbeschluss über Massnahmen des Bundes zur Verminderung der Drogenprobleme vom 20. Februar 1991. Bern, Bundeskanzlei, 1991
11. Federal Office of Public Health: Massnahmen des Bundes zur Verminderung der Drogenprobleme: Ein Grundlagenpapier des Bundesamtes für Gesundheitswesen. Bern, Federal Office of Public Health, 1991
12. Ali R, Auriacombe M, Casas M, Cottler L, Farrell M, Kleiber D, Kreuzer AR, Ogbome A, Rehm J, Ward P: Report of the External Panel on the Evaluation of the Swiss Scientific Studies of Medically Prescribed Narcotics to Drug Addicts. Geneva, Report to the World Health Organisation, 1998
13. Rapport de la Commission d'experts pour la révision de la loi fédérale du 3 octobre 19511
14. sur les stupéfiants à l'attention de la cheffe du Département fédéral de l'intérieur. Berne, Office fédéral de la santé publique, 1996
15. Canadian Health Services Research Foundation. The theory and practice of knowledge brokering in Canada's health system. 2003
16. Jackson-Bowers E, Kalucy L, Mc Intyre E: Focus on. Focus on knowledge brokering. Adelaide, Primary Health Care Research and Information Service, 2006
17. van Kammen J, de Savigny D, Sewankambo N: Using knowledge brokering to promote evidence-based policy-making: The need for support structures. Bull World Health Organ 2006; 84: 608-612. (Pubitemid 44338244)
18. Ritter A: How do drug policy makers access research evidence? Int J Drug Policy 2009; 20: 70-75
19. Anderson LM, Brownson RC, Fullilove MT, Teutsch SM, Novick LF, Fielding J, Land GH: Evidence-based public health policy and practice: Promises and limits. Am J Prev Med 2005; 28: 226-230. (Pubitemid 40724385)
20. Hanney SR, Gonzalez-Block MA, Buxton MJ, Kogan M: The utilisation of health research in policy-making: Concepts, examples and methods of assessment. Health Res Policy Syst 2003; 1: 2
21. Gregrich RJ: A note to researchers: Communicating science to policy makers and practitioners. J Subst Abuse Treat 2003; 25: 233-237. (Pubitemid 37518383)
22. Uchtenhagen A: The role of coalitions in drug policy. Some theoretical and observational considerations. Adicciones 2011; 23: 183-187
23. Sabatier P: The advocacy coalition framework: Revisions and relevance for Europe. J Eur Public Policy 1998; 5: 98-130
24. Freeman L: The Development of Social Network Analysis. Vancouver, Empirical Press, 2006
25. May CR, Mair F, Finch T, MacFarlane A, Dowrick C, Treweek S, Rapley T, Ballini L, Ong BN, Rogers A, et al: Development of a theory of implementation and integration: Normalization Process Theory. Implement Sci 2009; 4: 29
26. Wejnert B: Integrating models of diffusion of innovations: A conceptual framework. Annu Rev Sociol 2002; 28: 297-306
27. Rogers EM: Diffusion of Innovations, ed 5 New York, Free Press, 2003
28. Waddell S: Societal Learning and Change. Sheffield, Greenleaf Publishing, 2005
29. Law J, Hassard J: Actor Network Theory and After. Oxford, Blackwell, 1999
30. Latour B: Reassembling the Social: An Introduction to Actor-Network-Theory. Oxford, Oxford University Press, 2005
31. Callon M, Lascoumes P, Barthe Y: Acting in an Uncertain World. An Essay on Technical Democracy. Cambridge, MIT Press, 2009
32. Serduelt U: Politiknetzwerke in der städtischen Drogenpolitik von Bern, Chur, St. Gallen und Zürich. Zurich, University of Zurich, 2000
33. Kübler D: Beyond nimbyism. Urban conflict resolution in Swiss drug policies; in Khan U: Participation beyond the Ballot Box European Case Studies in State-Citizen Dialogue. London, UCL Press, 1999, pp 43-64
34. Kübler D: Politique de la drogue dans les villes suisses entre ordre et santé. Analyse des conflits de mise en oeuvre. Paris, L'Harmattan, 2000
35. Kübler D: Understanding policy change with the advocacy coalition framework: An application to Swiss Drug Policy. J Eur Public Policy 2001; 8
36. Grob P: Zürcher 'Needle Park'. Ein Stück Drogengeschichte und -politik 1968-2008 Zurich, Chronos, 2012
37. Mino A: Scientific Analysis of the Studies on Heroin or Morphine Controlled Delivery. Bern, 1990
38. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A: General study design and implementation rules. Foundation for social therapy, the connection between research and practice in drug therapy. Drogalkohol 1994; 187-198
39. Subcomission for Drug Issues: Drug Policy Scenarios. Bern, 1996
40. Mateo I, Sanchez-Guerra M, Combarros O, Llorca J, Infante J, Gonzalez-Garcõa J, et al: Lack of association between cathepsin D genetic polymorphism and Alzheimer disease in a Spanish sample. Am J Med Genet 2002; 114: 31-33
41. Jhoo JH, Park WY, Kim KW, Lee KH, Lee DY, Youn JC, et al: Lack of association of cathepsin D genetic polymorphism with Alzheimer's disease. Arch Gerontol Genet 2005; 41: 121-127
42. Li XQ, Chen D, Zhang ZX, Qu QM, Zhang JW: Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population. Dement Geriatr Cogn Disord 2004; 18: 115-119. (Pubitemid 39140359)
43. Ingegni T, Nocentini G, Mariani E, Spazzafumo L, Polidori MC, Cherubini A, Catani M, Cadini D, Senin U, Mecocci P: Cathepsin D polymorphism in Italian elderly subjects with sporadic late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16: 151-155. (Pubitemid 36737001)
44. Raygani A, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T: Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 2006; 1: 68-72. (Pubitemid 44466204)
45. Keikhaee M, Hashemi S, Najmabadi H, Noroozian M: C677T methylentetrahydrofulate reductase and angiotensin converting enzyme gene polymorphisms in patients with Alzheimer's disease in Iranian population. Neurochem Res 2006; 8: 1079-1083. (Pubitemid 44310318)
46. Heshmati Y, Mirabzadeh A, Feizzade G, Gilanipour M, Etminan M, Khoram Khorshid H, et al: A novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer's disease; extra-short alleles and accumulated allele homozygosity. Am J Med Genet B Neuropsychiatr Genet 2009; 2: 248-253
47. Fesahat F, Houshmand M, Panahi MS, Gharagozli K, Mirzajani F: Do haplogroups H and U act to increase the penetrance of Alzheimer's disease? Cell Mol Neurobiol 2007; 3: 329-334
48. Lindquist S, Nielsen J, Stokholm J, Schwartz M, Batbayli M, Ballegaard M, et al: Atypical early-onset Alzheimer's disease caused by the Iranian APP mutation. J Neurol Sci 2008; 1-2: 124-130
49. Vaisi-Raygani A, Kharrazi H, Rahimi Z, Pourmotabbed T: Frequencies of apolipoprotein E polymorphism in a healthy Kurdish population from Kermanshah, Iran. Hum Biol 2007; 5: 579-587. (Pubitemid 351587385)
50. Azizi Z, Noroozian M, Kaini-Moghaddam Z, Majlessi N: Association between NOS3 gene G894T polymorphism and late-onset Alzheimer disease in a sample from Iran. Alzheimer Dis Assoc Disord 2010; 2: 204-208
51. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Primary Care Version, ed 4. Washington, American Psychiatric Association, 1995
52. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force of Alzheimer's disease. Neurology 1984; 34: 939-944
53. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
54. Josef S, David WR, Nina I, Kaaren A: Molecular Cloning: Rapid Isolation of Mammalian DNA. New York, Cold Spring Harbour Laboratory Press, 2002, pp 628-630
55. Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, et al: Genetic associations between cathepsin D exon 2 C → T polymorphism and Alzheimer's disease, and pathological correlations with genotype. J Neurol Neurosurg Psychiatry 2006; 77: 515-517
56. McIlroy SP, Dynan KB, McGleenon BM, Lawson JT, Passmore AP: Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci Lett 1999; 273: 140-141. (Pubitemid 29428127)
57. Menzer G, Muller-Thomsen T, Meins W, Alberici A, Binetti G, Hock C, et al: Non-replication of association between cathepsin D genotype and late onset Alzheimer. Am J Med Genet 2001; 105: 179-182. (Pubitemid 32290584)
58. Albayrak O, Tirniceriu A, Riemenschneider M, Kurz A, Scherag A, Egensperger R: The cathepsin D (224C/T) polymorphism confers an increased risk to develop Alzheimer's disease in men. J Gerontol A Biol Sci Med Sci 2010; 65A:219-224
59. Matsui T, Morikawa Y, Tojo M, Okamura N, Maruyama M, Hirai H, et al: Cathepsin D polymorphism not associated with Alzheimer's disease in Japanese. Ann Neurol 2001; 49: 544-545. (Pubitemid 32281344)
60. Bhojaka TJ, DeKosky ST, Ganguli M, Kamboh MI: Genetic polymorphisms in the cathepsin D and interleukin-66 genes and the risk of Alzheimer's disease. Neurosci Lett 2000; 288: 21-24
61. Bertram L, Guenette S, Jones J, Keeney D, Mullin K, Crystal A, et al: No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease. Ann Neurol 2001; 49: 114-116. (Pubitemid 32163014)
62. Bagnoli S, Nacmias B, Tedde A, Guarnieri BM, Cellini E, Ciantelli M, et al: Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 2002; 328: 273-276. (Pubitemid 34876664)
63. Ingegni T, Nocentini G, Mariani E, Spazzafumo L, Polidori MC, Cherubini A, et al: Cathepsin D polymorphism in Italian elderly subjects with sporadic late-onset. Dement Geriatr Cogn Disord 2003; 16: 151-155. (Pubitemid 36737001)
64. Styczynska M, Religa D, Pfeffer A, Luczywek E, Wasiak B, Styczynski G, et al: Simultaneous analysis of five genetic risk factors in Polish patients with Alzheimer's disease. Neurosci Lett 2010; 344: 99-102
65. Byun Ho, Han NK, Lee HJ, Kim KB, Ko YG, Yoon G, et al: Cathepsin D and eukaryotic translation elongation factor 1 as promising markers of cellular senescence. Cancer Res 2009; 69: 4638-4647
66. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Meahlen J, et al: Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 2006; 129: 1438-1445. (Pubitemid 43999376)
67. Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W, et al: Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet 2006; 78: 988-998. (Pubitemid 43787690)
68. Yamashima T, Oikawa S: The role of lysosomal rupture in neuronal death. Progress Neurobiol 2009; 1: 16.